The company projects mid to high single-digit sales growth in 2025 at constant exchange rates, excluding hyperinflation effects, and low double-digit business EPS growth before foreign exchange and ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

"And we're not used to having somebody without a career at stake in the room at a senior level," said Hudson.

By Q1 2025, the average ASP for all biosimilars in this class is $1840. The insulin glargine biosimilar market share remained at 6% as of Q3 2024. Sanofi's competitive pricing strategy has kept Lantus ...

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Snapshot of the implementation used to generate figures and numerical results from the paper "Sharp Bounds for Continuous-Valued Treatment Effects with Unobserved ...

Sanofi is looking at ways to revive its flagging diabetes business, and yesterday revealed some of the new ideas it has up its sleeve. The company’s biggest seller is basal insulin Lantus ...